CM Life Sciences II Inc. Announces Separate Trading of its Shares of Class A Common Stock and Warrants, on or about April 15, 2021
CM Life Sciences II Inc. (Nasdaq: CMIIU) announced that holders of its units can trade shares of Class A common stock and redeemable warrants separately starting April 15, 2021. These will trade under the symbols 'CMII' for stock and 'CMIIW' for warrants, while unseparated units will continue under 'CMIIU.' Brokers must contact Continental Stock Transfer & Trust Company for separation. This move is designed to capitalize on opportunities within the life sciences sector, although investors should be aware of the risks associated with forward-looking statements.
- The ability for unit holders to separately trade Class A common stock and redeemable warrants could enhance liquidity for investors.
- Strategic focus on consolidating under-resourced companies in the life sciences sector presents growth potential.
- The press release includes forward-looking statements that carry inherent risks, indicating uncertainty in future business combinations.
- Investors may face dilution if significant capital raising occurs through future offerings.
CM Life Sciences II Inc. (Nasdaq: CMIIU) (the “Company”) today announced that holders of the Company’s units sold in its initial public offering may elect to separately trade the shares of Class A common stock and redeemable warrants included in its units commencing on or about April 15, 2021.
The shares of Class A common stock and warrants that are separated will trade on The Nasdaq Capital Market (“Nasdaq”) under the symbols “CMII” and “CMIIW,” respectively. Those units not separated will continue to trade on Nasdaq under the symbol “CMIIU.” No fractional warrants will be issued upon separation of the units and only whole warrants will trade.
Holders of the Company’s units will need to have their brokers contact Continental Stock Transfer & Trust Company, the Company’s transfer agent, in order to separate such units into shares of Class A common stock and redeemable warrants.
Registration statements relating to these securities became effective on February 22, 2021. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The offering was made only by means of a prospectus. Copies of the prospectus relating to this offering may be obtained from Jefferies LLC, Attn: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone: 877-821-7388 or by email: Prospectus_Department@Jefferies.com.
About the Company
The Company was founded to take advantage of a dynamic life science sector buoyed by innovation yet fragmented, where many companies are under-resourced and under-scaled. Significant and under-appreciated opportunities for consolidation are ready for engagement by a team versed in the trends and themes, and who can bring together the strongest of the new companies and management teams to capitalize on near- and far-term opportunities. For more information, please visit: https://cmlifesciencesspac.com/.
Cautionary Note Concerning Forward-Looking Statements
This press release contains statements that constitute “forward-looking statements,” including with respect to the Company’s search for an initial business combination. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s registration statement and final prospectus for the initial public offering filed with the U.S. Securities and Exchange Commission (the “SEC”). Copies are available on the SEC’s website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210413006075/en/
FAQ
What is the trading date for CM Life Sciences II Inc. shares and warrants?
What are the stock symbols for CM Life Sciences II Inc. after separating units?
How can unit holders separate their units into shares and warrants?
What does the forward-looking statement caution mean for CM Life Sciences II Inc. investors?
